Antimetastatic activities of heparins and modified heparins. Experimental evidence
Antimetastatic activities of heparins and modified heparins. Experimental evidence
复制标题
DOI：
10.1016/s0049-3848(10)70017-7
复制
发表时间：
2010-04-01
影响因子：
7.5
通讯作者：
Borsig, Lubor
中科院分区：
文献类型：
--
作者：
Borsig, Lubor
肝素通常用于预防或治疗癌症相关血栓栓塞。最近的临床证据表明，肝素和低分子量肝素可以提高癌症患者的生存率。来自各种动物模型的实验证据一致支持肝素减弱转移的能力。肝素除了具有抗凝活性外，还具有多种可能影响癌症进展的生物活性，包括：抑制乙酰肝素酶、阻断P-和L-选择素介导的细胞粘附以及抑制血管生成。肝素抗转移活性的描述是几项正在进行的研究的重点。这篇综述总结了肝素作为一种潜在的治疗癌症进展的生物学目前的实验证据。(C)2010爱思唯尔有限公司版权所有。
Heparin is commonly used for prevention or treatment of cancer-associated thromboembolism. Recent clinical evidence indicates that heparin, and low-molecular weight heparin improves survival of cancer patients. Experimental evidence from various animal models consistently supports the ability of heparin to attenuate metastasis. Heparin, apart from its anticoagulant activity contains a variety of biological activities possibly affecting cancer progression, including: inhibition of heparanase, blocking of P-and L-selectin mediated cell adhesion, and inhibition of angiogenesis. The delineation of antimetastatic activity of heparin is in the focus of several ongoing investigations. This review summarizes the current experimental evidence on the biology of heparin as a potential treatment cancer progression. (C) 2010 Elsevier Ltd. All rights reserved.